Sequent Scientific and Viyash Life Sciences are discussing a potential merger valued at Rs. 7000-8000 crore. Both companies' boards will meet to consider the deal, which could offer back-end synergies. Carlyle, a global private equity firm, holds shares in both firms. The merger aims to leverage Viyash's manufacturing capacity for Sequent's benefit.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.